Omeros (OMER) Total Non-Current Liabilities (2021 - 2026)
Omeros recorded quarterly Total Non-Current Liabilities of $265.5 million in Q1 2026, down 39.82% quarter-over-quarter from $441.2 million in Q4 2025, and down 40.24% year-over-year from $444.2 million in Q1 2025.
Omeros' Total Non-Current Liabilities history runs 6 years deep, the most recent figure standing at $265.5 million for Q1 2026.
- In Q1 2026, Total Non-Current Liabilities fell 40.24% year-over-year to $265.5 million; the TTM figure through Mar 2026 stood at $265.5 million (down 40.24% YoY), while the FY2025 annual figure was $441.2 million, down 3.08% from the prior year.
- Total Non-Current Liabilities came in at $265.5 million for Q1 2026 at Omeros, down from $441.2 million in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $507.0 million in Q3 2023 to a low of $251.2 million in Q2 2025.
- A 5-year average of $425.8 million and a median of $455.2 million in 2024 frame the typical range for Total Non-Current Liabilities.
- Across the five-year window, Total Non-Current Liabilities jumped 35.22% in 2023 and sank 47.54% in 2025, its largest moves.
- Omeros' Total Non-Current Liabilities stood at $504.8 million in 2022, then slipped by 20.54% to $401.2 million in 2023, then advanced by 13.47% to $455.2 million in 2024, then fell by 3.08% to $441.2 million in 2025, then tumbled by 39.82% to $265.5 million in 2026.
- According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $265.5 million, $441.2 million, and $253.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 11.03 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 42,980.09 |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 95.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 110.28 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 5.87 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 7.32 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 4.05 Bn |
| 10 | Omeros | 772.03 Mn | 636.71 Mn | 9.31 Mn | 265.48 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 265.48 Mn |
| Dec 31, 2025 | 441.16 Mn |
| Sep 30, 2025 | 253.66 Mn |
| Jun 30, 2025 | 251.17 Mn |
| Mar 31, 2025 | 444.21 Mn |
| Dec 31, 2024 | 455.19 Mn |
| Sep 30, 2024 | 464.41 Mn |
| Jun 30, 2024 | 478.82 Mn |
| Mar 31, 2024 | 506.73 Mn |
| Dec 31, 2023 | 401.16 Mn |
| Sep 30, 2023 | 507.02 Mn |
| Jun 30, 2023 | 506.42 Mn |
| Mar 31, 2023 | 504.74 Mn |
| Dec 31, 2022 | 504.84 Mn |
| Sep 30, 2022 | 502.87 Mn |
| Jun 30, 2022 | 377.38 Mn |
| Mar 31, 2022 | 373.27 Mn |
| Dec 31, 2021 | 394.37 Mn |